April 28, 2016 — Breast cancer patients undergoing treatment with trastuzumab-containing regimens should be monitored for heart damage regardless of age. This is among the findings of a new study from the Peter Munk Cardiac Centre, the Institute for Clinical Evaluative Sciences (ICES) and the Ted Rogers Centre for Heart Research, University Health Network (UHN). The study was published April 18 in the Journal of Clinical Oncology.


 

April 28, 2016 — Abbott and St. Jude Medical Inc. announced a definitive agreement for Abbott to acquire St. Jude Medical. The merger will create a premier medical device leader with top positions in high-growth cardiovascular markets, including atrial fibrillation, structural heart and heart failure as well as a leading position in the high-growth neuromodulation market. St. Jude Medical's strong positions in heart failure devices, atrial fibrillation and cardiac rhythm management complement Abbott's leading positions in coronary intervention and transcatheter mitral repair. 

The Department of Health and Human Services (HHS) issued a proposal to align and modernize how Medicare payments are tied to the cost and quality of patient care for hundreds of thousands of doctors and other clinicians.

April 27, 2016 — Imaging Advantage LLC, platform provider of cloud-based radiology service, announced the launch of a machine learning research initiative titled Singularity Healthcare. The initiative is being conducted with leading faculty members from the Massachusetts Institute of Technology and Harvard Medical School/Massachusetts General Hospital. 

Veniti Inc. announced the first successful treatment with the Vici Verto Venous Stent System of a patient suffering from post-thrombotic syndrome (PTS) associated with venous outflow obstruction.

Mitralign Inc. announced its Mitralign Percutaneous Annuloplasty System (MPAS) has received CE mark approval from its notified body, the British Standards Institution (BSI), for the treatment of functional mitral regurgitation (FMR).

The results of a secondary analysis of the SCOT-HEART trial show that coronary computed tomography angiography (CCTA) leads to a more appropriate and effective selection of invasive coronary angiography for patients with suspected angina due to coronary heart disease.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now